Abstract Number: 2832 • 2014 ACR/ARHP Annual Meeting
The Effect of Co-Medication with Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs on TNF Inhibitor Drug Survival in Patients with Ankylosing Spondylitis: Results from a Nationwide Prospective Study
Background/Purpose For rheumatoid arthritis it is well established that co-medication (co-med) with methotrexate (MTX) increases the efficacy and drug survival of TNF inhibitors (TNFi), while…Abstract Number: 2833 • 2014 ACR/ARHP Annual Meeting
SM101, a Novel Recombinant, Soluble, Human FcγIIB Receptor, in the Treatment of Systemic Lupus Erythematosus: Results of a Double-Blind, Placebo-Controlled Multicenter Study
Background/Purpose : SM101, which represents the human soluble non-glycosylated version of the Fcγ receptor IIB, binds to the Fc part of autoimmune complexes and inhibits…Abstract Number: 2834 • 2014 ACR/ARHP Annual Meeting
Correlation of Laboratory and Clinical Parameters with British Isles Lupus Assessment Group Response in an Open-Label Extension Study of Epratuzumab in Systemic Lupus Erythematosus
Background/Purpose Epratuzumab is a monoclonal antibody in development for the treatment of systemic lupus erythematosus (SLE) that binds CD22, promoting the natural inhibitory function of…Abstract Number: 2794 • 2014 ACR/ARHP Annual Meeting
Deletion of the Inhibitory Receptor Motif, ITIM, on DC-STAMP Alters Osteoclast Differentiation and Function
Background/Purpose DC-STAMP (Dendritic Cell-Specific Transmembrane Protein), a 7-pass transmembrane protein essential for cell-to-cell fusion during osteoclast (OC) differentiation, is expressed on the cell surface of…Abstract Number: 2795 • 2014 ACR/ARHP Annual Meeting
Blockade of IL-6R Signaling by Sarilumab Suppressed Circulating Markers of Bone Resorption and Synovial Damage in Rheumatoid Arthritis Patients from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Background/Purpose Rheumatoid arthritis (RA) patients develop bone and joint damage due to chronic inflammation mediated by critical cytokines, eg, IL-6. Pre-clinical studies have implicated IL-6…Abstract Number: 2796 • 2014 ACR/ARHP Annual Meeting
A Novel Mouse Model of Osteochondromagenesis By Deleting NFATc1 in Mesenchymal Progenitors and Postnatal Chondrocytes
Background/Purpose: Osteochondromas are the most common benign bone tumor and are characterized by cartilage-capped bony projections from the external surface of bone. These lesions may…Abstract Number: 2797 • 2014 ACR/ARHP Annual Meeting
Anti-Citrullinated Proteins Antibodies Promotes Osteoclastogenesis and Bone Destruction in Rheumatoid Arthritis
Background/Purpose Presence of anti-citrullinated protein antibodies (ACPA) is a major risk factor for bone erosion in rheumatoid arthritis (RA) and antibodies against modified citrullinated vimentin…Abstract Number: 2798 • 2014 ACR/ARHP Annual Meeting
C5orf30 a Novel Regulator of Inflammation and Tissue Damage in Rheumatoid Arthritis
Background/Purpose A recent genome wide association study identified the variant rs26232 in the first intron of the uncharacterized gene, C5orf30, as a rheumatoid arthritis (RA)…Abstract Number: 2799 • 2014 ACR/ARHP Annual Meeting
The Differential Impact of Obesity on the Pathogenesis of RA or Preclinical Models Is Contingent on the Disease Status
Background/Purpose: Studies were performed to determine the significance of obesity in the pathogenesis of rheumatoid arthritis (RA) and experimental arthritis models. Methods: Chronic and acute…Abstract Number: 2800 • 2014 ACR/ARHP Annual Meeting
Tofacitinib Regulates Synovial Angiogenesis in Psoriatic Arthritis through Induction of Negative Feedback Inhibitors
Background/Purpose: Psoriatic Arthritis (PsA) is a common, chronic immune-mediated inflammatory disease, characterised by synovitis, progressive destruction of articular cartilage/bone, and is associated with psoriasis. Janus…Abstract Number: 2801 • 2014 ACR/ARHP Annual Meeting
IL-38: A New Factor in Rheumatoid Arthritis
Background/Purpose: IL-38 (IL-1F10) was originally described as an IL-1 family cytokine, and named IL-1HY2. The IL-38 gene is located in the IL-1 family cluster on…Abstract Number: 2802 • 2014 ACR/ARHP Annual Meeting
Non-Canonical NF-Kappab Signaling Promotes Angiogenesis in a Novel 3D Spheroid Model of Rheumatoid Arthritis Synovial Inflammation
Background/Purpose: Angiogenesis is regarded as a switch from acute to chronic inflammation and thus plays a crucial role in rheumatoid arthritis disease progression. This process…Abstract Number: 2803 • 2014 ACR/ARHP Annual Meeting
Methotrexate Impacts the Effects of Tofacitinib, but Not Tocilizumab, on Clinically Relevant Biomarkers in Human Primary Cell–Based BioMAP® Disease Models: Can We Utilize in Vitro Models to Predict Clinical Outcomes?
Background/Purpose: A number of trials have shown that adding MTX benefits some, but not all, biologics and small molecules to treat RA. Specifically, though treatment…Abstract Number: 2804 • 2014 ACR/ARHP Annual Meeting
Rituximab in IgG4-Related Disease: A Large Single-Center Experience
Background/Purpose IgG4-related disease (IgG4-RD) is an immune-mediated multiorgan, fibroinflammatory disease often associated with an elevated serum IgG4 concentration. The diagnosis hinges on characteristic histopathologic features. …Abstract Number: 2805 • 2014 ACR/ARHP Annual Meeting
IgG4-Related Disease: Baseline Features in 100 Patients with Biopsy-Proven Disease
Background/Purpose IgG4-related disease (IgG4-RD) has emerged as an immune-mediated disease that links multiple fibro-inflammatory conditions through common pathology and pathophysiologic mechanisms. Most of the literature…
ACR Meeting Abstracts